. Author manuscript; available in PMC: 2017 Oct 1.

Published in final edited form as: Neuromodulation. 2016 May 12;19(7):717–723. doi: 10.1111/ner.12446

Table 2.

Pre and post DBS outcomes.

	Baseline	6 month post implant	p-value
AUA-SI	10.67±6.29	10.82±6.04	0.64
QOL	3.24±1.77	2.52±1.30	0.03
OAB-q	12.06±6.55	12.36±8.25	0.79
SHIM	8.70±8.26	8.63±7.66	0.70
Total LEDD	1233.10±573.8666	1044.38±645.76	0.07
Dopamine agonist LEDD	207.42±206.12	136.67±159.17	0.02
PGI-I		3.76±1.28

Legend: Numerical values correspond to mean ±standard deviation. AUA-SI=American Urological Association symptom index, QOL= Quality of Life score, OAB-q=Overactive Bladder 8 Questionnaire, SHIM=The Sexual Health Inventory for Men, PGI-I=The Patient Global Impression of Improvement Score, LEDD=Levodopa equivalent daily dose.